中药联合核苷和核苷酸类药物治疗慢性乙型肝炎的系统评价

任爽; 张华; 胡鑫才; 刘平

中药联合核苷和核苷酸类药物治疗慢性乙型肝炎的系统评价

1. 上海中医药大学附属曙光医院肝病研究所
2. 江西中医学院附属医院
3. 上海中医药大学上海高校中医内科学E研究院

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2993
- HTML全文浏览量: 17
- PDF下载量: 757
- 被引次数: 0
出版历程
- 出版日期: 2013-04-20

Meta-analysis of the clinical efficacy of combination therapy with traditional Chinese medicine and nucleoside analogue antiviral drugs for chronic hepatitis B

摘要

摘要:
目的系统评价中药联合核苷和核苷酸类药物治疗慢性乙型肝炎的疗效。方法检索中国期刊全文数据库、万方中国学位论文全文数据库、维普期刊全文数据库、中国生物医学文献数据库、MEDLINE、Embase、BIOSIS等数据库,纳入国内外公开发表的以中药联合核苷和核苷酸类药物为试验组,核苷和核苷酸类药物为对照组的治疗慢性乙型肝炎的随机对照试验(RCT);采用Jadad评分来评估各个研究的质量;研究数据的统计学分析使用Cochrane协作网提供的Revman5.0软件完成,采用固定或随机效应模型汇总研究结果。结果最终纳入14个随机对照试验,1篇研究方法学Jadad评分为3分,1篇为2分,其余为1分,共1386例慢性乙型肝炎患者,其中试验组703例,对照组683例。对于14篇的Meta分析显示:在治疗6个月和12个月时肝功能复常率(ALT、AST)和病毒学指标(HBeAg阴转率、HBeAg血清转换率、HBV DNA阴转率),联合干预组均优于对照组,两组比较差异有统计学意义;对于YMDD变异发生率,在6个月时两组差异无统计学意义,而继续治疗至12个月,联合干预组优于对照组。结论本系统评价结果表明,6个月以...
- 肝炎,乙型,慢性 /
- 抗病毒药 /
- 核苷类 /
- 核苷酸类
Abstract:
Objective To investigate whether the collected randomized controlled trials (RCTs) published to date have shown that supplemental application of traditional Chinese medicine (TCM) improves the outcome of chronic hepatitis B (CHB) patients treated with nucleoside analogue antiviral drugs.Methods Literature collections on the Chinese Biomedical Literature Database, the Chinese Academic Journal Full-text Database, the Chinese Scientific Journals Database, PubMed, and Embase were searched from inception to July 2012 to identify publications of RCTs comparing the therapeutic efficacy of TCM combined with nucleoside analogues lamivudine (LDM) , adefovir (ADV) , entecavir (ETV) ) to treat CHB.Inclusion criteria included: patients with CHB for more than six months, serum HbsAg-positivity, 2 × upper normal limit (ULN) ≤alanine aminotransferase (ALT) ≤10 × ULN, hepatitis B virus (HBV) DNA-positivity, and no previous antiviral therapy for six months prior to study;a control group receiving a single nucleoside analogue;study treatment time of at least three months.The methodological quality of included RCTs was assessed using the Jadad scale.The meta-analysis was carried out with RevMan 5.0 software.Heterogeneity was examined by Chi-squared test.Pooled data was analyzed by the fixed effects model or random effects model, according to presence of heterogeneity.Publication bias was assessed by funnel plot asymmetry.Results A total of 14 RCTs were included in the analysis and comprised 1386 CHB patients with 703 in the trial groups and 683 in the control groups.Only one study had moderate-high methodological quality (Jadad score: 3) , and the remaining studies had low methodological quality (Jadad score: 2, n = 1;1, n = 12) .The outcome measures included: ALT normalization rate, aspartate aminotransferase (AST) normalization rate, hepatitis B e antigen (HbeAg) -negativity rate, HBeAg seroconversion rate, HBV DNA-negativity rate, and incidence of the LAM-resistance YMDD mutation.Meta-analysis indicated that the combined treatment strategy produced significantly better outcome in ALT normalization, AST normalization, HBeAg-negativity, and HBV DNA-negativity compared to the single nucleoside analogue alone treatment strategy after treating for 24 and 48 weeks (all P < 0.05) .The YMDD mutation rates were not significantly different between the groups after 24 weeks of treatment, but were significantly better in the combined treatment strategy group then in the single nucleoside analogue alone treatment strategy group after 48 weeks of treatment (P < 0.05) .Conclusion RCTs examining the benefit of supplementing nucleoside analogue antiviral drugs with TCM treatment show an improved therapeutic efficacy for chronic hepatitis B patients, especially when administered for 48 weeks.
- hepatitis B /
- chronic /
- antiviral agents /
- nucleosides

HTML全文

参考文献(20)

[1]Fowell AJ, Iredale JP.Emerging therapies for liver fibrosis[J].Dig Dis, 2006, 24 (12) :174-183.

[2]Mareellin P, Chang TY, Lin SG, et al.Adefovir dipivoxil forthe treatment of hepatitis B e anti gen-positive chronic hep-atitis B[J].N Engl J Ned, 2003, 348 (9) :808-816.

[3]Shi LN.Long-term efficacy and safety of entecavir in thetreatment of HBeAg-positive chronic hepatitis B[J].J MedRes, 2011, 40 (9) :146-148. (in Chinese) 施丽妮.恩替卡韦在HBeAg阳性的慢性乙型肝炎患者中的长期疗效及安全性[J].医学研究杂志, 2011, 40 (9) :146-148.

[4] Chinese Society of Hepatology and Chinese Society of Infec-tious Diseases, Chinese Medical Association.The guideline ofprevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :I-XVI. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[5]Jadad AR, Moore RA, Carroll D, et al.Assessing the qualityof reports of randomized clinical trials:is blinding necessary?[J].Control Clin Trials, 1996, 17 (1) :1-12.

[6]FENG H, ZHANG YH.Effect of chinese medicine therapy forstrengthening-Pi and nourishing-Shen in preventing lami-vudine induced YMDD mutation and its immunologic mecha-nism[J].Chin J Integr Med, 2010, 16 (1) :19-22.

[7]Chen ZX, Zhang SJ, Hu HT.Clinical efficacy of traditional Chi-nese medicine in preventing YMDD mutation in chronic hepatitisB[J].Chin J Integr Tradit West Med on Liver, 2005, 15 (3) :168-170. (in Chinese) 陈泽雄, 张诗军, 胡洪涛.中药预防慢性乙型肝炎YMDD变异的临床观察[J].中西医结合肝病杂志, 2005, 15 (3) :168-170.

[8]He YH, He J.Clinical study of adefovir dipivoxil combined withsyndrome differentiation-based traditional Chinese medicinetreatment in HBeAg-positive patients with chronic hepatitis B[J].Jiangsu J Traditi Chin Med, 2010, 42 (5) :22-23. (in Chi-nese) 何义华, 何坚.阿德福韦酯联合辨证使用中药治疗HBeAg阳性慢性乙肝的临床研究[J].江苏中医药, 2010, 42 (5) :22-23.

[9]Chen PQ, Chi XL, Tian GJ, et al.Treatment of Chronic Hepati-tis B by Lamivudine Combined with Lingzhi Capsule:A ClinicalObservation of 30 Cases[J].New J Tradit Chin Med, 2007, 39 (3) :78-79. (in Chinese) 陈培琼, 池晓玲, 田广俊, 等.拉米夫定联合灵芝胶囊治疗慢性乙型肝炎30例临床观察[J].新中医, 2007, 39 (3) :78-79.

[10]Jiang J, Fu CS, Zhang JC, et al.Clinical efficacy of Yigan-kang combined with lamivudine in treatment of chronic hepa-titis B:a report of 34 cases[J].Shandong Med J, 2007, 47 (17) :76-78. (in Chinese) 姜捷, 付春生, 张建春, 等.乙肝康联合拉米夫定治疗慢性乙型病毒性肝炎34例疗效观察[J].山东医药, 2007, 47 (17) :76-78.

[11]Tang BZ, Li M, Gao YQ.Curative effect of yidu recipe in trea-ting chronic hepatitis b patients of gan-shen yin-deficiencyand damp-heat syndrome type and its influence of t-cell sub-sets[J].Chin J Integr Tradit West Med, 2010, 30 (8) :823-827. (in Chinese) 汤伯宗, 李曼, 高月求.抑毒方治疗肝肾阴虚兼湿热型慢性乙型肝炎的疗效及对T细胞亚群的影响[J].中国中西医结合杂志, 2010, 30 (8) :823-827.

[12]Wu J, Wang JY.Therapeutic efficacy of lamivudine combinedwith traditional Chinese medicine in treatment of chronic hepati-tis B:a report of 76 cases[J].Chin J IntegrTradit West Med onLiver, 2007, 17 (3) :172-173. (in Chinese) 吴建, 王际云.拉米夫定联合中药治疗慢性乙型肝炎76例[J].中西医结合肝病杂志, 2007, 17 (3) :172-173.

[13]Lu LY, Lan J, Huang S, et al.Clinical efficacy of Chineseherb Chuiling decoction combined with lamivudine in treat-ment of chronic hepatitis B[J].Guangxi Med J, 2005, 27 (6) :816-817. (in Chinese) 陆用连, 兰晶, 黄绍, 等.中药垂苓汤联合拉米夫定治疗慢性病毒性乙型肝炎临床疗效观察[J].广西医学, 2005, 27 (6) :816-817.

[14]Chen Z.Clinical efficacy of adefovir dipivoxil combined withFuzheng Huayu capsules in treatment of hepatitis B cirrhosis[J].Chin J Geriatr Care, 2010, 8 (2) :40-42. (in Chinese) 陈钟.阿德福韦酯联合扶正化瘀胶囊治疗乙型肝炎肝硬化的临床观察[J].中国老年保健医学, 2010, 8 (2) :40-42.

[15]Zhang XY, Li F.Clinical study of entecavir combined withFuzheng Huayu capsules in treating chronic hepatitis B[J].Shandong Med J, 2010, 50 (44) :79-81. (in Chinese) 张孝盈, 李菲.恩替卡韦联合扶正化瘀胶囊治疗慢性乙型肝炎临床研究[J].山东医药, 2010, 50 (44) :79-81.

[16]Han ZY, Han SY, Han JH.Clinical control observation on treat-ment of chronic hepatitis B according to TCM in combinationwith lamivudine[J].P Clin Med, 2004, 13 (12) :945-946. (inChinese) 韩子岩, 韩树颖, 韩经寰.中药联合拉米夫定治疗慢性乙肝的临床对照观察[J].临床医药实践杂志, 2004, 13 (12) :945-946.

[17]Cui DG, Gong WF.Clinical research on treating chronic hep-atitis B by the joint use of Yin and Yang syndrome classifica-tion prescription and lamivudine[J].Asia-Pacific TraditMed, 2007, 3 (7) :62-63. (in Chinese) 崔德广, 龚伟峰.按阴阳辨证分类组方联合拉米夫定治疗慢性乙型肝炎临床研究[J].亚太传统医药, 2007, 3 (7) :62-63.

[18]Lai JQ, Liu GA, Pan XN, et al.Clinical efficacy of entecavircombined with Fuzheng Huayu capsules in treatment of hep-atitis B cirrhosis and its ultrasound manifestation:an analysisof 64 cases[J].J Clin Hepatol, 2011, 14 (6) :458-459. (in Chinese) 赖江琼, 刘国安, 潘兴南, 等.恩替卡韦联合扶正化瘀胶囊治疗64例乙型肝炎肝硬化超声表现及临床疗效分析[J].实用肝脏病杂志, 2011, 14 (6) :458-459.

[19]Zhang QK.Clinical efficacy of Yigan decoction combined withlamivudine in treatment of chronic hepatitis B[J].J ClinHepatol, 2011, 14 (6) :458-459. (in Chinese) 张清科.乙肝汤联合拉米夫定治疗慢性乙型肝炎临床疗效观察[J].中国医药指南, 2010, 8 (10) :112-113.

[20]Ye LX.Field Epidemiology[M].Beijing:People's MedicalPublishing House, 2009:368. (in Chinese) 叶临湘.现场流行病学[M].北京:人民卫生出版社, 2009:368.

施引文献

资源附件(0)

访问统计